慢性病中的卢比普:随机二期临床试验中的线粒体功能和多氨酸的洞察
Shun Watanabe1,2, Masaaki Nakayama3, Takashi Yokoo4
1Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan.
Science advances
|August 29, 2025
概括
通过改善功能标志物,卢比普可能有助于减缓慢性病 (CKD) 的进展. 这项研究发现该药物对缓解慢性病患者的衰退是安全的,并且可能有益的.
科学领域:
- 肝脏病学
- 胃肠病学
- 药理学
背景情况:
- 便秘是慢性病 (CKD) 进展的一个危险因素.
- 尿液中毒素会在CKD中积累,导致疾病的严重程度.
- 目前的CKD治疗通常集中在控制症状和减缓进展.
研究的目的:
- 评估 lubiprostone 的有效性和安全性在IIIb- IV 阶段的慢性病患者中.
- 评估 lubiprostone 对尿液中毒素水平和功能的影响.
- 探索 lubiprostone 可能影响 CKD 进展的机制.
主要方法:
- 这是一项2期随机双盲,安慰剂对照试验,涉及150名患有IIIb-IV期慢性脏病的患者.
- 患者接受了lubiprostone (8或16微克) 或安慰剂24周.
- 主要终点是硫酸水平的变化;次要终点包括其他尿素毒素和功能标志物.
主要成果:
- 卢比普没有显著改变尿液中毒素水平.
- 16 微克的 lubiprostone 剂量改善或保持估计的球膜过率 (eGFR) 和它的斜率.
- 在安慰剂和 lubiprostone 组中观察到轻度至中度的胃肠道事件.
- 多组学分析表明,皮质调节了肠道微生物的亚格马丁通路,并增加了精子,可能改善线粒体功能.
结论:
- 在慢性病患者中,尤以16微克的剂量,露比具有缓解衰弱的潜力.
- 这种药物被发现是安全的,并且在研究的CKD群体中耐受良好.
- 卢比是一种新的治疗方案,可能通过肠道- 微生物群- 脏途径来控制慢性病的进展.
相关概念视频
01:24Chronic Kidney Disease II: Clinical Manifestations
85
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
85
01:21Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
01:25Chronic Kidney Disease I: Introduction
65
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
65
01:28Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
01:18Chronic Kidney Disease IV: Nursing Management
54
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
54
01:29Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128